MCRB earnings analysis
What we found in MCRB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Seres Therapeutics reported no revenue for Q1 2026, with a net loss of $19.9 million compared to a profit of $32.7 million in Q1 2025. Expenses decreased significantly to $21.3 million from $27.2 million, mainly due to reduced general and administrative costs, and the absence of manufacturing service costs post-transaction with Nestlé. The company is focusing on its pipeline, requiring additional funding after Q3 2026, while facing increased scrutiny on cash flow and compliance with evolving regulations.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Net Loss Decline
- Reported a net loss of $19.9 million, a significant decline from a net income of $32.7 million in Q1 2025.
- Operational Expense Reduction
- Total operating expenses fell to $21.3 million from $27.2 million, primarily due to lower general and administrative costs.
- Pipeline Focus
- The company continues to advance project SER-155 despite pausing additional investment in Phase 2 studies pending funding.
- Decreased Workforce
- Announced a 30% workforce reduction as part of cost-cutting measures implemented in February 2026.
- Sufficient Cash Until Funding Needed
- Held $29.8 million in cash and cash equivalents, but anticipates the need for additional funding after Q3 2026.
- Cash Flow Implications
- Reported cash used in operations was $16.4 million for Q1 2026, indicating ongoing liquidity pressures.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Substantial Doubt of Going Concern
- Management noted substantial doubt about the ability to continue operations for at least 12 months based on current cash resources.
- Dependence on Funding
- Requires additional capital following Q3 2026 to fund operations and development activities.
- Ongoing Regulatory Scrutiny
- Potential changes in laws regarding pricing and marketing may adversely impact financial condition.
What they said about what is next.
Additional funding anticipated after Q3 2026 to support ongoing operations.
The filing reads worse than the one before it.
What came before.
- 10-K · March 12, 2026
- Seres Therapeutics (MCRB) positions itself as a leader in live biotherapeutics with a proprietary MbTx platform, GMP manufacturing capabilities, and multiple pipeline candidates (SER-155, SER-603, SER-147). The company…
- 10-Q · August 6, 2025
- Seres Therapeutics reported an improved quarterly operating result: loss from continuing operations narrowed to $(19,855) for Q2 2025 versus $(26,196) in Q2 2024, and GAAP net loss per share improved to $(2.27) from…
- 10-Q · May 7, 2025
- Seres reported Q1 2025 net income of $32,682 (thousands) and diluted EPS of $3.75, driven primarily by a $52,181 gain on the sale of the VOWST business. Operating results remain challenged: loss from operations was…
- 10-K · March 13, 2025
- The 10-K repositions the company as a clinical-stage live-biotherapeutics developer focused on advancing SER-155 after the September 2024 sale of VOWST to Nestlé. The filing highlights strong Phase 1b Cohort 2 results…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MCRB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever